- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03620539
Sauna Bathing to Improve Vascular Health of Adults With Heart Disease
Effects of Sauna Bathing on Cerebrovascular Function in Middle-aged to Older Adults With Heart Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mounting evidence suggests that heat therapy may improve cardiovascular health. Recent analyses of a large cohort of middle-aged to older Finnish men have established that frequent sauna bathing is associated with a reduced risk of cardiovascular mortality, of developing dementia and Alzheimer's disease, and of developing hypertension. Given the observational nature of these relationships, it remains unknown if the beneficial effects of sauna bathing can be directly attributed to heat exposure.
The objective of this study is to test the primary hypothesis that 8 weeks of sauna bathing improves flow-mediated dilation, a measure of blood vessel health, in middle-aged to older adults (50-70 yrs) with stable coronary artery disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H1T1N6
- Cardiovascular Prevention and Rehabilitation Centre of the Montreal Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A history of angiographic coronary disease: ≥70% arterial diameter narrowing of at least one major epicardial coronary artery and/or prior coronary revascularization and/or documented prior acute coronary syndrome and/or perfusion defect during exercise testing or pharmacological stimulation
- Stable medication doses (≥4 weeks) prior to enrolment
- Body mass index <35 kg/m2
Exclusion Criteria:
- Recent (<3 months) coronary artery disease-related hospitalization or change in angina pattern
- Unstable angina
- Ejection fraction <40% and/or clinical evidence of heart failure
- Significant valvular heart disease
- Uncontrolled hypertension (>180/110 mmHg)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Participants randomized to the control condition will be asked to maintain their normal daily habits.
|
|
|
Experimental: Sauna
The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
|
Sauna bathing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow-mediated dilation
Time Frame: Change from baseline after 8 weeks
|
Brachial artery flow-mediated dilation in response to 5 minutes of forearm occlusion
|
Change from baseline after 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-occlusion reactive hyperaemia (AUC)
Time Frame: Change from baseline after 8 weeks
|
Vascular conductance area-under-the-curve during reactive hyperaemia induced by 5 minutes of forearm occlusion
|
Change from baseline after 8 weeks
|
|
Post-occlusion reactive hyperaemia (Peak)
Time Frame: Change from baseline after 8 weeks
|
Peak vascular conductance during reactive hyperaemia induced by 5 minutes of forearm occlusion
|
Change from baseline after 8 weeks
|
|
Local skin heating-induced vasodilation
Time Frame: Change from baseline after 8 weeks
|
Plateau of the cutaneous vascular conductance response during local heating of the skin to 39°C
|
Change from baseline after 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood pressure
Time Frame: Change from baseline after 8 weeks
|
Systolic blood pressure at rest
|
Change from baseline after 8 weeks
|
|
Central arterial stiffness
Time Frame: Change from baseline after 8 weeks
|
Carotid-femoral pulse wave velocity
|
Change from baseline after 8 weeks
|
|
Heart rate variability
Time Frame: Change from baseline after 8 weeks
|
Resting levels of heart rate variability
|
Change from baseline after 8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICM2017-2312
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.